---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338273"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2026-08-06T20:34:51+00:00"
generated_at: "2026-08-06T20:36:40.548095+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verrica Q2 net loss $13.2M; YCANTH dispensed units up 28% sequentially, 46% YoY

## Summary
- Q2 total revenue $5.9M (down from $12.7M YoY due to $8M milestone in prior year); YCANTH net product revenue $5.1M (+18.7% QoQ, +12.3% YoY).
- Q2 net loss $13.2M ($0.62/share) vs net income $0.2M in Q2 2025; non-GAAP net loss $10.2M ($0.48/share).
- YCANTH dispensed applicator units reached 19,626 in Q2, up 28.3% QoQ and 46.1% YoY; record quarterly demand.
- Entered $27.5M credit facility with Chairman Paul B. Manning; cash runway could extend into 2028.
- Phase 3 common warts topline data expected mid-2027; COVE-2 and COVE-3 trials recruiting; settled 2022 class action for $1.7M after insurance.

## SEC filing metadata
- accession: 0001193125-26-338273
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2026-08-06T20:34:51+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/0001193125-26-338273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338273
- JSON: https://secwatch.observer/filing/0001193125-26-338273.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.